About Obsidio
Obsidio is a company based in Solana Beach (United States) founded in 2018 by Ali Khademhosseini, Rahmi Oklu, and Ehsan Jabbarzadeh was acquired by Boston Scientific in August 2022. Obsidio has raised $3 million across 4 funding rounds from investors including Boston Scientific, Good Growth Capital and National Heart, Lung, and Blood Institute. Obsidio operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
- Headquarter Solana Beach, United States
- Founders Ali Khademhosseini, Rahmi Oklu, Ehsan Jabbarzadeh
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$3 M (USD)
in 4 rounds
-
Latest Funding Round
$2.1 M (USD), Grant
Jul 16, 2021
-
Investors
Boston Scientific
& 4 more
-
Employee Count
Not available
-
Acquired by
Boston Scientific
(Aug 15, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Obsidio
Unlock access to complete
Unlock access to complete
Funding Insights of Obsidio
Obsidio has successfully raised a total of $3M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $2.1 million completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Obsidio
Obsidio has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Boston Scientific, Good Growth Capital and National Heart, Lung, and Blood Institute.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are provided by IAG Capital Partners.
|
Locked | Locked | Locked | |
|
Early-stage investments are made in life sciences and technologies.
|
Locked | Locked | Locked | |
|
Venture capital fund backed by the US Government
|
Locked | Locked | Locked |
Investor details for Obsidio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Obsidio
Investment portfolio details for Obsidio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Obsidio
Detailed financials for Obsidio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Obsidio Comparisons
Peer comparison for Obsidio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Obsidio
Obsidio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
Dental implants and regenerative dentistry products are developed.
|
|
| Locked | Locked | Locked |
RNA-editing technologies are provided for precision medicine applications.
|
Detailed competitors of Obsidio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Obsidio
Complete news archive for Obsidio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Obsidio
Obsidio was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Obsidio is headquartered in Solana Beach, United States. It is registered at Solana Beach, California, United States.
Ehsan Jabbarzadeh is the current CEO of Obsidio. They have also founded this company.
Obsidio is a funded company, having raised a total of $3M across 4 funding rounds to date.
Obsidio was founded in 2018 in Solana Beach, United States, within the medical technology sector focused on biomaterials. A shear-thinning biomaterial technology is being advanced for minimally invasive delivery of a polymer via catheter to stop blood flow. The material is designed to thin under pressure for injection and solidify upon pressure release, enabling applications such as hemorrhage control, tumor vessel occlusion, arteriovenous malformation prevention, and aneurysm treatment.
Obsidio's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Obsidio has 5 investors. Key investors include Boston Scientific, Good Growth Capital, National Heart, Lung, and Blood Institute, IAG Capital Partners, and America’s Seed Fund.